COMP <GO>
IBRX vs PCVX // FORWARD P/E MULTIPLE
ImmunityBio Inc. (NASDAQ) VS. Vaxcyte Inc. (NASDAQ) • 15-METRIC TALLY: IBRX 4
— PCVX 7
▲ FORWARD P/E MULTIPLE LEADER: PCVX
LAST: $8.29 (-5.15%) • MKT CAP: $9.26B
forward-pe
29.0x
LAST: $62.03 (-0.93%) • MKT CAP: $9.85B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBRX VS. PCVX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBRX | PCVX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.30% | -27.60% | +0.30 | IBRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.33% | -6.79% | +3.46 | IBRX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -33.50% | -26.50 | PCVX | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 0.00% | -60.00 | PCVX | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 19.80% | +160.20 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 18.11 | -17.66 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | IBRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 50.1 | -1.10 | PCVX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.07 | -0.02 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 29.0x | 23.0x | +6.00 | PCVX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.26B | $9.85B | -$591.2M | PCVX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBRX REV | PCVX REV | IBRX GROSS % | PCVX GROSS % | IBRX FCF | PCVX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $0 | 99.3% | — | -$308.8M | -$669.3M |
| FY 2024 | $14.7M | $0 | 100.0% | — | -$398.1M | -$475.1M |
| FY 2023 | $622.0K | $0 | — | — | -$366.8M | -$296.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBRX // BETA 1.05
PCVX // BETA 1.07